Belgium· BE-AMP-SAM506977-00
Cinqaero 10 mg/ml
A reslizumab product containing reslizumab, registered in Belgium by Teva. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Reslizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC R03DX08 (reslizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Reslizumab · ATC R03DX08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Reslizumab
- Manufacturer
- Teva
- Country
- Belgium (BE)
- ATC code
- R03DX08
- ATC class
- Reslizumab
- Defined daily dose
- 7.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7724628
- be_apb3688454
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Reslizumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCINQAEROTeva B.V., Haarlem
- FinlandCINQAEROTeva B.V.
- IcelandCinqaeroTeva B.V.*
- PolandCinqaeroTeva B.V.
- SwedenCINQAERO 10 mg/ml Koncentrat till infusionsvätska, lösningTeva B.V.
- United StatesCINQAIRTeva Respiratory, LLC
- IrelandCINQAERO 10 mg/mL concentrate for solution for infusionTeva B.V.
- United KingdomCinqaero 100mg/10ml concentrate for solution for infusion vialsTeva UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Cinqaero
- Iceland · Cinqaero
- Liechtenstein · Cinqaero
- Norway · Cinqaero
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/149cb1fd-7491-4ae3-be52-e33dcc0cdba1 GET /v1/drugs/149cb1fd-7491-4ae3-be52-e33dcc0cdba1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Cinqaero 10 mg/ml",
"name_fr": "Cinqaero 10 mg/ml",
"name_nl": "Cinqaero 10 mg/ml",
"amp_code": "SAM506977-00",
"strengths": [
"10.0000",
"10.0000",
"0.4600"
],
"pack_count": 2,
"substances": [
"Reslizumab",
"Sucrose",
"Sodium"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Reslizumab",
"authorisation_numbers": [
"EU/1/16/1125/001",
"EU/1/16/1125/003"
]
}See everything about reslizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.